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Summary
PRINCIPLES: Apolipoprotein E (ApoE), an important glycoprotein in the transport, uptake and redistribution of
cholesterol, is necessary in nerve tissue repair. The APOE gene (APOE) is involved in neurodegenerative diseases, the
best-known association being that between the APOE ε4 allele and Alzheimer’s disease. Multiple sclerosis (MS) is a
chronic inflammatory neurological disease. The aim of this study was to assess (multicentre assessment) the possible
influence of the APOE gene on the susceptibility of primary progressive MS (PPMS) in Hungary.
METHODS: Polymerase chain reaction and restriction fragment length polymorphism were carried out on DNA
isolated from 135 volunteers.
RESULTS: The number of PPMS patients without the ε2 allele was found to be remarkably high, whilst the ε2 allele
was overrepresented in the RRMS group. A markedly high frequency of the ε4 allele was found in the PPMS group and a
very low frequency in the HC group. With regards to the clinical parameters, significant differences were observed
between the RRMS and PPMS groups. Differences were also detected regarding the EDSS and MSSS scores when the
patients were grouped by the presence or absence of the ε2 allele. All of the observed differences in the clinical
parameters disappeared when the patients were further stratified by the type of MS.
CONCLUSIONS: Our findings suggest that the presence of the ε2 and ε4 alleles may play a role in the development
of the disease. However, if any type of the disease has already developed the alleles show no association with the clinical
parameters.
Key words: Apolipoprotein E gene (APOE); Genetics; Multiple sclerosis (MS); Primary progressive (PP); Single
nucleotide polymorphism (SNP)
Introduction
Apolipoprotein E (ApoE) plays important roles in the transport, uptake and redistribution of cholesterol, which is
necessary in the repair of nerve tissue. While it primarily functions as a lipid transporter, it is also linked to
atherosclerosis, cognitive function, immunoregulation, neurite outgrowth, brain trauma and infectious diseases [1]. The
APOE gene (APOE) is additionally involved in neurodegenerative diseases; the best-known association is that between
the APOE ε4 allele and Alzheimer’s disease [3]. Multiple sclerosis (MS) is a chronic inflammatory neurological disease
caused by numerous factors. The heterogeneous nature of the disease leads to different clinical manifestations. In the
majority of MS patients the disease begins with a relapsing course (relapsing-remitting form; RRMS), characterised by
relapses and remissions, followed by a progressive phase (secondary progressive MS; SPMS). The pathological hallmark
is the primary inflammation and the secondary neurodegeneration. In a smaller subset of patients, the relapsing phase is
absent and the disease progresses from the very beginning (primary progressive form; PPMS). In this subtype, the
neurodegeneration is the driving force [4].
Two single base polymorphisms within exon 4 of the APOE, at codons 112 and 158, result in three common alleles
(ε2, ε3 and ε4); the corresponding protein variants ApoE2, E3 and E4 are distinguishable by having different
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combinations of the amino acids arginine and cysteine at these positions [1, 2]. ApoE is produced in various organs and
tissues, predominantly in the liver and by the astrocytes in the brain. ApoE3 seems to be the normal form, while ApoE2
and ApoE4 can each be dysfunctional. The protein is a glycoprotein that contains 299 amino acids, with a molecular
weight of 34 kDa.
The literature reports on the role of APOE in MS are controversial (table 1). In addition, no Hungarian data is
available regarding the APOE status of MS patients. Consequently, our aim was to evaluate the role of the APOE gene in
Hungarian PPMS patients. The hypothesis of present study was that the ε4 allele is associated with progression, while the
ε2 allele is rather protective.
Table 1: Summary of studies investigating the association between APOE and MS.
First author Country Number of MS subtype
patients
Findings
Cocco Sardinia 773 RR; 98 PP Gender-specific association between ε4 and PP
Chapman Israel 47 RR ε4 allele increases rate of disease progression
Chapman Israel 172 RR; 31 SP; 2 PP ε4 allele associated with faster progression of disability
Fazekas Austria 76 RR; 5 SP; 2 PP More extensive tissue destruction or less efficient repair in carriers of the ε4 allele
Fazekas Austria 253 RR; 97 SP; 24 PP An association of ε4 allele with a more severe course
Høgh Denmark 104 RR; 29 PP; 105 SP ε4/ε4 genotype risk for developing MS and faster disease progression
Schmidt USA 379 RR; 30 PP; 182 SP; 19
PR
Association between ε4 and a more severe form and between ε2 and mild disease
Pinholt Denmark 249 RR; 94 SP; 42 PP ε4 allele associated with faster progression
Evangelou UK 52 RR; 32 SP; 11 PP ε4 allele associated with more rapid progression
Al-Shammri Kuwait 33 RR; 5 RP; 1benign MS No association (only trend toward) between disease severity and ε4 allele
Ferri Italy 161 RR No association with occurrence of MS
Niino Japan 95 RR; 40 SP No association with disease progression
Weatherby UK 162 RR; 188 SP; 20 PP No association with occurrence or clinical course
Zwemmer The Netherlands 159 RR; 159 SP; 90 PP Disease severity not associated to carriership of ε4 or ε2
Masterman Sweden 124 benign; 140 severe No significant differences between the benign and severe MS
Santos Portugal 34 PP; 184 other form ε4 not associated to disease progression only in a subset of patients with <10 yrs
disease duration
Portaccio Italy 75 RR; 40 BMS; 49 SP; 9
PP
No association with disease course and severity
Bonetti Finland 459 MS trio families No association
Savettieri Italy 319 RR; 90 SP; 19 PP Association between ε2 allele and longer disease duration
Ballerini Italy 32 CP; 34 stable MS ε2 allele has protective role against the onset of the progression form
Kantarci Turkey 221 MS Gender-specific association between APOE ε2 and lesser disease severity
Abbreviations: APOE= apolipoprotein E gene; BMS = benign multiple sclerosis; CP = chronic progressive; MS = multiple sclerosis; PP = primary
progressive; RR = relapsing remitting; SP = secondary progressive;
Patients and methods
Patients
All patients gave their informed consent for participation in accordance with the Declaration of Helsinki (1964) and the
study was approved by the local ethics committee (protocol no. 16/2006). Over a period of one year (between 2006 June
and 2007 June), participation in the study was offered to PPMS patients who were consecutively referred to one of the 5
involved Hungarian MS Centres at the regular check-up every 5 months. The APOE genotype was determined from the
blood of 45 PPMS patients, 45 age- and sex-matched RRMS patients and 45 healthy controls (HC). The two latter groups
served as control groups for the PPMS group. A total of 13 of the 45 PPMS patients were followed up at the MS
Outpatient Unit of the Department of Neurology at the University of Szeged, 12 patients at the Department of Neurology
at the University of Pécs, 7 patients at the Department of Neurology at Ferenc Jahn Hospital in Budapest, 7 patients at the
Department of Neurology at the County Hospital in Kecskemét, and 6 patients were followed up at the Department of
Neurology at the University of Debrecen. The RRMS patients and HC subjects were selected according to age and sex
from Szeged. Clinical data (the Expanded Disability Status Scale (EDSS) score [5], date of birth, year of diagnosis and
onset of the disease) were collected by using the up-to-date MS register. The Multiple Sclerosis Severity Score (MSSS)
[6] and the progression index (PI; the ratio between the EDSS score and the disease duration in years) were also
determined. The EDSS scores the disability by evaluating the degree of neurological impairment and it has steps from 0
(normal) to 10 (death due to MS). The MSSS gives a hint as to the severity of the disease, expressed numerically via the
extent of disability and the disease duration. The RRMS patients met the McDonald diagnostic criteria [7]. The PPMS
patients had undergone at least one year of disease progression and had had a positive brain or spinal cord MRI or
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positive cerebrospinal fluid [8]. The patients were relapse-free and were not taking steroids for at least 1 month before the
assessment. In Hungary, a central database of healthy controls for genetic research is not available. We therefore offered
study participation to age and sex-matched attendants and relatives of MS patients and to healthy staff at the clinic. If the
health inclusion criteria were satisfied (no current acute or chronic physical or mental illness), the participant signed an
informed consent form.
Methods
DNA analysis and genotyping
Genomic DNA was extracted from 1 ml EDTA-treated peripheral blood. For extraction, the GenisolTM Maxi-Prep Kit
(ABgene House, Epsom, UK) was used.
To determine the genotype, we applied a polymerase chain reaction (PCR) on a 2720 Thermal Cycler (produced by
PE Applied Biosystems) by using the primers 5’-TCCAAGGAGCTGCAGGCG-3’ and
5’-CCGGCCTGGTACACTGCC-3’. The oligonucleotides were from the Biological Research Centre, Hungarian
Academy of Sciences, Szeged.
The primers created a restriction site for the Hin6I enzyme (Fermentas) (5’-G^CGC-3’). The digestion products were
resolved on polyacrylamide gel and detected under ultraviolet light after staining with ethidium bromide. The ε2 allele
gave visible fragments of 91 and 83 bp, the ε3 allele gave fragments of 91 and 48 bp, and the ε4 allele gave fragments of
72 and 48 bp.
Statistical analysis
T-test and variance analysis were used to detect the differences among the three groups with regards to the demographic
and clinical parameters. We grouped the subjects by the presence or absence of the ε2, ε3 or ε4 alleles because the sample
size did not allow groups to be made for all possible genotypes. The Pearson chi squared test was performed to study the
distribution of the alleles by the investigated groups. The p values were calculated on the basis of adjusted residual values.
These values revealed the extent of the discrepancy between the observed and the expected frequencies in the cell
(residual) in the examined group and standardised it. The combined effect of the MS course and the alleles on the clinical
parameters was analysed with a two-way analysis of variance. Due to the multiple comparisons, the level of significance
was chosen to be p <0.005. For all statistical analyses, the SPSS 15.0 statistical package was used.
Results
The population analysed was in Hardy-Weinberg equilibrium, because the value of the goodness-of-fit test was p = 0.082
(Chi2 = 9.78, d.f = 5). The demographic data on the three groups are displayed in table 2. As the groups were age- and
sex-matched, there were no differences by gender or mean age (p = 0.998). The age at onset in the PPMS patients was
higher and the disease duration was shorter than in the RRMS patients but not significantly (p = 0.404 and p = 0.316,
respectively). In the PPMS form, the EDSS score, the PI and the MSSS values were higher compared with those for the
RRMS group (p <0.001).
Due to the low number of subjects with absence of the ε3 allele (5 RRMS and 1PPMS patients) grouping patients by
this allele was not possible (table 3). Neither є2/є2 nor є4/є4 homozygote genotype was detected.
Table 4a and 4b show the occurrence of ε2 and ε4 alleles in the investigated groups. The number of the PPMS patients
without the ε2 allele was found to be remarkably high (p <0.001), whilst the ε2 allele was overrepresented in the RRMS
group (p <0.003) (table 4a). In addition, the pairwise comparisons indicated that the difference between the RRMS and
HC groups was also significant (p <0.001).
The presence of the ε4 allele was typical in the PPMS and the RRMS groups (table 4b). A markedly high frequency of
this allele was found in the PPMS group (p <0.001) and a very low frequency in the HC group (p <0.001). The pairwise
comparisons revealed that the frequency of the ε4 allele was higher also in the RRMS group than that in the HC group (p
<0.05) and was twice as frequent as in the PPMS group (p <0.005).
With regards to the clinical parameters (EDSS, PI and MSSS), significant differences were observed between the
RRMS and PPMS groups (p <0.001 for all parameters; table 2). Differences were also detected regarding the EDSS and
MSSS scores when the patients were grouped by the presence or absence of the ε2 allele (p <0.004 and p <0.001,
respectively; table 5). As for the є4 allele, there were no differences found in any of the clinical parameters on the p =
0.005 decision level but on the p = 0.05 level the MSSS value differed significantly (p = 0.045). All of the observed
differences in the clinical parameters disappeared when the patients were further stratified by the type of MS.
Two-way analysis of the combined effect of the two variables (presence or absence of the alleles and type of MS)
revealed that the difference in the clinical parameters could only be attributed to the type of MS (table 6). Interaction
between these variables could not be detected.
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Table 2: Demographic and clinical data of the three groups.
Group Patients number
Male/Female
Age
(years)
Age at onset
(years)
Disease duration
(years)
EDSS PI MSSS
PPMS 23/22 49.1 ± 10.5 38.0 ± 9.4 11.1 ± 8.9 5.7 ±1.8 0.96 ± 1.13 7.2 ± 2.0
RRMS 23/22 49.2 ± 9.8 36.3 ± 9.5 12.9 ±8.0 2.8 ± 1.9 0.32 ± 0.35 3.2 ± 2.5
HC 23/22 49.0 ± 10.6 – – – – –
p – 0.998 0.404 0.316 <0.001 <0.001 <0.001
Values are given as mean ± SD
Abbreviations: EDSS = Expanded Disability Status Scale; HC = healthy control; MSSS = Multiple Sclerosis Severity Score; PI = progression index; PPMS
= primary progressive multiple sclerosis; RRMS = relapsing-remitting multiple sclerosis
Table 3: Distribution of all APOE genotypes by the investigated groups.
MS patientsAPOE gene
PPMS (n = 45) RRMS (n = 45) HC (n = 45)
Total
Genotype
ε2/ε2 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
ε2/ε3 3 (6.7%) 17 (37.8%) 17 (37.8%) 37 (27.4)
ε2/ε4 1 (2.2%) 5 (11.1%) 0 (0.0%) 6 (4.4%)
ε3/ε3 18 (40.0%) 17 (37.8%) 24 (53.3%) 59 (43.7%)
ε3/ε4 23 (51.1%) 6 (13.3%) 4 (8.9%) 33 (24.4%)
ε4/ε4 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Total 45 (100.0%) 45 (100.0%) 45 (100.0%) 135 (100.0%)
Abbreviations: APOE = apolipoprotein E gene; HC = healthy control; PPMS = primary progressive multiple sclerosis; RRMS = relapsing-remitting multiple
sclerosis
Table 4a: The occurrence of the ε2 allele in the investigated groups.
HC PPMS RRMS Total
Count 28 41 23 92
% within group 62.2 91.1 51.1 68.1
non ε2
Adjusted residual (p) –1.0 (0.317) 4.0 (<0.001) –3.0 (0.003)
Count 17 4 22 43
% within group 37.8 8.9 48.9 31.9
ε2
Adjusted residual (p) 1.0 (0.317) –4.0 (<0.001) 3.0 (0.003)
Count 45 45 45 135Total
% within group 100.0 100.0 100.0 100.0
Pearson Chi-Square p <0.001
Table 4b: The occurrence of the ε4 allele in the investigated groups.
HC PPMS RRMS Total
Count 41 21 34 96
% within group 91.1 46.7 75.6 71.1
non ε4
Adjusted residual (p) 3.6 (<0.001) –4.4 (<0.001) 0.8 (0.424)
Count 4 24 11 39
% within group 8.9 53.3 24.4 28.9
ε4
Adjusted residual (p) –3.6 (<0.001) 4.4 (<0.001) –0.8 (0.424)
Count 45 45 45 135
% within group 100.0 100.0 100.0 100.0
Total
Pearson Chi-Square p <0.001
Abbreviations: HC = healthy control; PPMS = primary progressive multiple sclerosis; RRMS = relapsing-remitting multiple sclerosis
Short communication Swiss Med Wkly. 2010;140:w13119 · www.smw.ch E4
Table 5: Mean values of the measured clinical parameters of MS groups dependant on having or not having the ε2 or ε4 alleles.
PPMS RRMS PPMS and RRMS
N = 41 N = 4 N = 45 N = 23 N = 22 N = 45 N = 64 N = 26 N = 90
non ε2 ε2 Total
p
non ε2 ε2 Total
p
non ε2 ε2 Total
p
Disease duration
(year)
11.2 ± 8.9 10.3 ± 10.2 11.1 ± 8.9 0.872 12.7 ± 6.9 13.1 ± 9.2 12.9 ± 8.0 0.842 11.7 ± 8.2 12.7±9.2 12.0 ± 8.5 0.618
EDSS 5.6 ± 1.8 6.3 ± 2.1 5.7 ± 1.8 0.586 3.0 ± 2.1 2.6 ± 1.7 2.8 ± 1.9 0.429 4.7 ± 2.2 3.2±2.2 4.2 ± 2.3 0.004
PI 1.0 ± 1.2 0.6 ± 0.6 1.0 ± 1.1 0.475 0.3 ± 0.3 0.4 ± 0.4 0.3 ± 0.4 0.456 0.7 ± 1.0 0.4±0.5 0.6 ± 0.9 0.093
MSSS 7.2 ± 2.1 7.0 ± 0.8 7.2 ± 2.0 0.858 3.5 ± 2.6 3.0 ± 2.4 3.2 ± 2.5 0.534 5.9 ± 2.9 3.6±2.6 5.2 ± 3.0 0.001
PPMS RRMS PPMS and RRMS
N = 21 N = 24 N = 45 N = 34 N = 11 N = 45 N = 55 N = 35 N = 90
non ε4 ε4 Total
p
non ε4 ε4 Total
p
non ε4 ε4 Total
P
Disease duration
(year)
10.7 ± 8.4 11.5 ± 9.5 11.1 ± 8.9 0.768 14.2 ± 8.0 8.8 ± 6.9 12.9 ± 8.0 0.052 12.9 ± 8.3 10.6 ± 8.7 12.0 ± 8.5 0.226
EDSS 5.6 ± 1.9 5.7 ± 1.7 5.7 ± 1.8 0.934 3.0 ± 1.9 2.1 ± 1.8 2.8 ± 1.9 0.169 4.0 ± 2.3 4.6 ± 2.4 4.2 ± 2.3 0.287
PI 0.9 ± 0.9 1.0 ± 1.3 1.0 ± 1.1 0.819 0.3 ± 0.4 0.3 ± 0.3 0.3 ± 0.4 0.851 0.6 ± 0.7 0.8 ± 1.2 0.6 ± 0.9 0.242
MSSS 7.0 ± 2.2 7.4 ± 1.8 7.2 ± 2.0 0.530 3.3 ± 2.5 3.0 ± 2.7 3.2 ± 2.5 0.759 4.7 ± 3.0 6.0 ± 2.9 5.2 ± 3.0 0.045
Values are given as mean ± SD
Abbreviations: EDSS = Expanded Disability Status Scale; MSSS = Multiple Sclerosis Severity Score; PI = progression index; PPMS = primary progressive
multiple sclerosis; RRMS= relapsing-remitting multiple sclerosis
Table 6: Results of the two-way analysis of variance.
p
Dependent variable: EDSS –
Type of MS <0.001
ε2 0.866
Grouping variables
Type of MS* ε2 0.327
Dependent variable: MSSS –
Type of MS <0.001
ε2 0.631
Grouping variables
Type of MS* ε2 0.838
Abbreviations: EDSS = Expanded Disability Status Scale; MSSS = Multiple Sclerosis Severity Score; MS = multiple sclerosis
Discussion
The literature reports on the role of APOE in MS are controversial, with claims that the presence [9–18] or absence
[19–28] of the APOE є4 allele is connected with the susceptibility to the disease or its severity. The role of the APOE
gene in MS has been extensively studied in recent years, but the debate remains open (table 1). Studies on the APOE
status in the Hungarian MS population have not been published so far, though the role of chromosome 19 was raised by
Rajda et al. [29].
In the literature, the information relating to the genetic background of PPMS patients is incomplete because of the low
number of such patients [10, 12–15, 17, 18, 24, 25]. Only two studies on APOE analysis (from Sardinia and the
Netherlands) involved a larger PPMS group than that in the present study (table 1) [11, 26]. The prevalence of MS in the
Netherlands is 76 per 100,000 inhabitants [30], while in Sardinia it is approximately 2.3-fold higher than in Hungary [31,
32]. Accordingly, our group (approximately 7% of the Hungarian PPMS population) comprises of a comparatively large
sample, considering that the Hungarian prevalence is 62 per 100,000, the population of Hungary is 10 million and 11% of
Hungarian MS patients have the PPMS form [31]. The study from Sardinia revealed that the ε4 allele increases the risk of
PPMS, but only in women [11] whereas the study from the Netherlands did not confirm any association.
A recent meta-analysis by Burwick et al. of the results from a pooled analysis (353 PPMS cases) did not provide any
evidence of an association between the ε2 or ε4 carrier status in PPMS [20]. The pooled analysis was performed on the
results of 11 published (from 10 different countries) and one unpublished article, which is an average of 32 ± 26 PPMS
subjects per article. However, this meta-analysis did not include the results from Sardinia with 98 PPMS patients [11] or
from Denmark with 42 PPMS patients [16]. Cocco et al. detected a gender-specific association between the ε4 allele and
the PPMS course whilst Pinholt et al. found that the ε4 allele is associated with faster progression (table 1). A study from
a country geographically adjacent to Hungary (Austria) detected an association between the ε4 allele and rapid
progression (24 PPMS subjects) [14].
The present study did not consider the genotype-phenotype relationship, however, in the series in the study by
Masterman et al. the APOE ε3/ε4 genotype was more common in severe MS than in benign MS [21]. Fazekas et al. found
that patients carrying the ε3/ε4 genotype exhibited a significantly higher black hole ratio, demonstrating the disabling
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effect of the є4 allele [13]. The black hole ratio ((T1-LL/T2-LL)*100), calculated by the total lesion load on proton
density weighted (T2-LL) and T1 weighted scans (T1-LL), indicates the proportion of more severe tissue destruction
among MS lesions. A study from Denmark indicated that the є4/є4 homozygote genotype is a risk factor for MS and
determines the clinical progression [15].
Similarly as in other studies, we could not identify patients homozygous for the є4 allele [10, 11, 22, 34], most
probably because of the low number in the overall examined population. In contrast, 2.1–7.7% of the patients were
genotyped as є4/є4 in studies from Denmark [15, 16], Sweden [21] and Kuwait [19].
The frequencies of the APOE alleles vary worldwide. The predominant allele for most populations is the ε3 allele
(70–80%), which is often considered to be the ancestral allele. We found this to be the most frequent allele in our
population (68.9% in the PPMS group, 63.3% in the RRMS group and 76.7% in the HC group). While the proportion of
ε4 carriers increases steadily from 10–15% in southern Europe to 40-50% in the north, the proportion of ε2 allele carriers
is slightly higher in central Europe than in the south or the north [1]. The distributions of the є4 allele in this study
exhibited a wide range, from 4.4% to 26.7%, and its frequency was outstandingly high in the PPMS group. The є2 allele
frequency was underrepresented in the PPMS group (only 4.4%).
Concerning the relationship between the age at onset and the APOE polymorphisms, a previous study concluded that
the є4 allele is associated with an earlier age of onset in MS patients [10]. We did not observe a significant association
between either the є4 or the є2 allele and the disease duration.
Fewer studies have investigated the association of the ε2 allele in MS. Some authors reported evidence of a protective
effect of the ε2 allele [18, 33], but the meta-analysis by Burwick et al. disputed this [20]. Our results provide support for
an association between carrying the є2 allele and more favourable disease parameters. Furthermore, this is in line with the
findings of Savettieri et al. [24], Kantarci et al. [35] and a study which demonstrated that patients with the є3/є2 genotype
had a significantly reduced and delayed risk of chronic progressive MS [33]. The presence of the є2 allele may possibly
exert a protective effect against progression.
The strength of the present study is that it was based on a comparatively large number of a subpopulation with a rare
disease and examined a wide range of clinical parameters.
The limitations of this study are the low number of subjects in the control groups; consequently increases in the
number of RRMS patients and healthy controls are clearly needed. In addition, further SNP assessments (HLA) related to
disease progression or association, and longitudinal follow-ups completed with magnetic resonance findings are suggested
for a reliable result.
The present study is the first that has examined the possible association involving the APOE status in the population
of Hungarian PPMS patients. Based on the observed differential occurrence of the ε2 allele in the PPMS and the RRMS
groups, we suspect that the presence of this allele makes the patients susceptible to the RRMS course. The observed
distribution of the ε4 allele across the groups indicated that this allele is linked with both forms of the disease but with a
higher propensity to the PPMS course. Our findings suggest that the presence of the ε2 and ε4 alleles may play a role in
the development of the disease. However, if any type of the disease has already developed the alleles show no association
with the clinical parameters.
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